BiomX Inc. (NYSEAMERICAN:PHGE – Get Free Report) saw a significant decline in short interest during the month of February. As of February 15th, there was short interest totalling 9,800 shares, a decline of 60.3% from the January 31st total of 24,700 shares. Approximately 0.1% of the company’s stock are sold short. Based on an average trading volume of 86,000 shares, the days-to-cover ratio is currently 0.1 days.
BiomX Stock Performance
Shares of BiomX stock opened at $0.62 on Friday. The firm has a market capitalization of $11.35 million, a PE ratio of -0.19 and a beta of 1.27. BiomX has a 12 month low of $0.48 and a 12 month high of $8.55.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright restated a “buy” rating and set a $2.00 price objective on shares of BiomX in a research report on Wednesday, January 8th.
BiomX Company Profile
BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).
Featured Articles
- Five stocks we like better than BiomX
- Election Stocks: How Elections Affect the Stock Market
- Autodesk Designs Value for Investors: Uptrend Set to Continue
- How to start investing in penny stocks
- Anheuser-Busch Stock Rallies—Is the King of Beers Back?
- How is Compound Interest Calculated?
- MarketBeat Week in Review – 02/24 – 02/28
Receive News & Ratings for BiomX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiomX and related companies with MarketBeat.com's FREE daily email newsletter.
